Lifecare ASA

Regulatory Filings • Jun 6, 2024

LIFE Sterilization protocol ready for the production line

LIFE Sterilization protocol ready for the production line

Bergen, Norway, June 6th, 2024: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), announces that the company has concluded the sterilization

protocol for production preparations, to be implemented in the automated

sensor production.

The Lifecare organization is working on preparations for automated production

after a successful pilot production at the end of Q1. Part of these

preparations has also been to finalize a procedure for sterilizing the

sensors, including both the advanced chemistry and sensitive electronics. In

our early product development, we have applied Gamma radiation as sterilizing

method, being costly and complex in a logistics perspective.

Lifecare has now concluded on a protocol for a sterilization based on exposing

the implant for UV-light and Ozone. The method is gentle, timesaving and very

cost-effective, compared to alternative sterilization methods.

- This method can easily be implemented in the production line and scaled up

in an automated production. The method of combining UV-light and Ozone is well

proven, cost efficient and only takes a few minutes, says CEO Joacim Holter at

Lifecare.

Lifecare, in collaboration with the Norwegian University of Life Sciences

(NMBU), has carried out trials and analysis, and can therefore document that

the method meets the high standards necessary for our medical device.

Finalizing the sterilization protocol has also been important in the

preparations towards the planned longevity studies (veterinary), as the sensor

with electronics will be fully implanted under the patient's skin. In both

perspectives the implant must be sterile to not cause infection or irritation.

Lifecare's required specifications for sterilization has been clear all along

for this important part of sensor production. In the sterilization process,

Lifecare is dependent not to expose the sensor's advanced chemistry and

electronics to damage. Therefore, we have spent a lot of resources over a

period of time to conclude a method that satisfies the requirements for

sterilization and is gentle enough for the sensor. We have tested various

methods, and our investigations show that heat, pressure, gamma radiation,

chemicals and gas cannot be used.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42